Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Poseida Therapeutics, Inc. (PSTX : NSDQ)

• Company Description    Poseida Therapeutics Inc. is a clinical-stage biopharmaceutical company. It focuses on developing therapeutics for high unmet medical needs. The company is developing a pipeline of solutions for the treatment of hematological malignancies and solid tumors, as well as vivo programs for liver-directed gene therapies for rare diseases. In addition, it offers CAR-T therapies for the treatment for cancer. Poseida Therapeutics Inc. is based in San Diego, California. Number of Employees: 263

• Price / Volume Information    Yesterday's Closing Price: $2.10 Daily Weekly Monthly 20 Day Moving Average: 269,256 shares Shares Outstanding: 62.71 (millions) Market Capitalization: $131.68 (millions) Beta: 1.00 52 Week High: $11.10 52 Week Low: $1.83 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -31.60% -22.96% 12 Week -41.01% -35.15% Year To Date -69.16% -63.76%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 9390 Towne Centre Drive Suite 200 - SAN DIEGO,CA 92121 USA ph: 858-779-3100 fax: - None http://www.poseida.com

• General Corporate Information    Officers Mark J. Gergen - Chief Executive Officer and Director Eric Ostertag - Executive Chairman and Director Johanna M. Mylet - Chief Financial Officer Cynthia Collins - Director Luke Corning - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 73730P108 SIC: 2836 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/22 Next Expected EPS Date: 08/11/22 Share - Related Items Shares Outstanding: 62.71 Most Recent Split Date: (:1) Beta: 1.00 Market Capitalization: $131.68 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.69 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-3.19 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 4.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: 1.75% Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/11/22

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 1.27 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: -50.00% vs. Previous Quarter: -4,750.00% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -95.41% ROE 03/31/22 - -97.02 12/31/21 - -69.39 09/30/21 - -78.72 ROA 03/31/22 - -53.67 12/31/21 - -42.96 09/30/21 - -51.38 Current Ratio 03/31/22 - 4.34 12/31/21 - 4.94 09/30/21 - 6.44 Quick Ratio 03/31/22 - 4.34 12/31/21 - 4.94 09/30/21 - 6.44 Operating Margin 03/31/22 - - 12/31/21 - - 09/30/21 - - Net Margin 03/31/22 - - 12/31/21 - - 09/30/21 - - Pre-Tax Margin 03/31/22 - -442.92 12/31/21 - -400.07 09/30/21 - - Book Value 03/31/22 - 1.65 12/31/21 - 2.50 09/30/21 - 2.41 Inventory Turnover 03/31/22 - - 12/31/21 - - 09/30/21 - - Debt-to-Equity 03/31/22 - 0.56 12/31/21 - 0.19 09/30/21 - 0.20 Debt-to-Capital 03/31/22 - 35.85 12/31/21 - 15.82 09/30/21 - 16.33

Powered by Zacks Investment Research ©